+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
NEULANDLAB

Neuland Laboratories Share Price

₹19,675.00 +632 (3.32%)
Near 52W High of ₹20089.00

03 Aug, 2026 3:52 PM (IST)

Neuland Laboratories live price: ₹19,675.00. It opened at ₹19,149 vs previous close ₹19,043; intraday high/low: ₹19,912/₹19,005. The 50 & 200 DMA stand at ₹18,065.20/₹15,857.50.

Neuland Laboratories Performance

  • Today's Low
  • ₹19,005
  • Today's High
  • ₹19,912
  • 52 Week Low
  • ₹11,500
  • 52 Week High
  • ₹20,089
  • Open Price₹19,149
  • Previous Close₹19,043
  • Volume49,070
  • 50 DMA₹18,065.20
  • 100 DMA₹16,974.30
  • 200 DMA₹15,857.50

Neuland Laboratories Chart

Investment Returns

  • Over 1 Month + 3.62%
  • Over 3 Month + 31.14%
  • Over 6 Month + 50%
  • Over 1 Year + 51.15%

Smart Investing Starts Here Start SIP with Neuland Laboratories for Steady Growth!

Invest Now

Neuland Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 69.3
  • PEG Ratio
  • 1.7
  • Market Cap Cr
  • 25,243
  • P/B Ratio
  • 13.5
  • Average True Range
  • 625.8
  • EPS
  • 283.7
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 331.5
  • RSI
  • 62.15
  • MFI
  • 49.63

Latest Stock News Updates

Neuland Laboratories Ltd - 524558 - Intimation Under Regulation 30 Of SEBI Listing Regulations

Intimation under Regulation 30 of SEBI Listing Regulations

Neuland Laboratories Ltd - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Q1FY27 Earnings Call Intimation

Neuland Laboratories Ltd - 524558 - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026

Neuland Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2026

Neuland Laboratories Financials

Neuland Laboratories Technicals

EMA & SMA

Current Price
₹19,675.00
+ 632 (3.32%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹18,894.10
  • 50 Day
  • ₹18,065.20
  • 100 Day
  • ₹16,974.30
  • 200 Day
  • ₹15,857.50

Resistance and Support

19530.67 Pivot Speed
  • R3 20,963.30
  • R2 20,437.70
  • R1 20,056.30
  • S1 19,149.30
  • S2 18,623.70
  • S3 18,242.30

Neuland Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-05 Quarterly Results
2026-05-12 Audited Results & Final Dividend
2026-02-09 Quarterly Results
2025-11-07 Quarterly Results
2025-07-31 Quarterly Results
Date Purpose Remarks
2026-07-24 FINAL Rs.34.00 per share(340%)Final Dividend
2025-07-18 FINAL Rs.12.00 per share(120%)Final Dividend
2022-07-15 FINAL Rs.5.00 per share(50%)Final Dividend
View Neuland Laboratories Dividend History Arrow

Neuland Laboratories Shareholding Pattern

32.62%
29.79%
21.08%
12.66%
3.86%

About Neuland Laboratories

Neuland Laboratories engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. View More
  • NSE Symbol
  • NEULANDLAB
  • BSE Symbol
  • 524558
  • Executive Director,Managing Director,Chief Executive Officer
  • D Saharsh Rao
  • ISIN
  • INE794A01010

Similar Stocks to Neuland Laboratories

Neuland Laboratories FAQs

Neuland Laboratories share price is ₹19,675 As on 04 August, 2026 | 00:25

The Market Cap of Neuland Laboratories is ₹25242.8 Cr As on 04 August, 2026 | 00:25

The P/E ratio of Neuland Laboratories is 69.3 As on 04 August, 2026 | 00:25

The PB ratio of Neuland Laboratories is 13.5 As on 04 August, 2026 | 00:25

The 52 week High & Low of Neuland Laboratories is ₹20089/₹11500 respectively As on 04 August, 2026 | 00:25

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23